Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

摘要

The programmed-death ligand 1 (PD-L1) and pro-grammed-death 1 (PD-1) pathway, plays a role in immune-mediated destruction of cancer cells,1'2 and is a pivotal immune checkpoint pathway. Tumors can evade antitumor immune activity by exploiting upregulated PD-14 expression in the tumor microenvironment. The binding of PD-L1 to its receptors PD-1 and B7.1 down-regulates T-cell activation and in turn prevents T-cell-induced cytotoxicity.2'3 Preventing this interaction can lead to enhanced T-cell priming and results in immune cells (IC) attacking and killing cancer cells.